Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

Colorectal cancer (CRC) is the second most common cause of death from cancer in the US and the most prevalent malignant tumor ...

It was "Strike Out Cancer Night" at the Kenosha ballpark. KENOSHA, Wis. - Tuesday night, June 24, was a night to celebrate at ...

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety ...

Colorectal cancer (CRC) is the second most common cause of death from cancer in the United States (US) and the most prevalent ...

The Push For Your Tush 5K/10K Walk/Run is Colorectal Cancer Canada’s (CCC) largest annual fundraising initiative in support ...

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

Get Instant Summarized Text (Gist) Cytokine-induced killer (CIK) cell therapy, combined with chemotherapy or surgery, improves overall and progression-free survival in colorectal cancer patients ...

Physical activity for cancer survivors supported by recent research; CAPABLE helps cancer survivors find their physical ...

A groundbreaking clinical trial funded by the Canadian Cancer Society (CCS) shows that physical activity can significantly ...